Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP187-V2B
- Development stage
- Phase 2
- Lead developer
- Forward Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FP187-V2B is a proprietary oral formulation of dimethyl fumarate (DMF) developed by Forward Pharma. It is designed as a delayed and slow-release version of DMF, an immune modulator that acts primarily through the activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway and the inhibition of the NF-κB pathway. These mechanisms contribute to its anti-inflammatory and cytoprotective effects. FP187-V2B specifically refers to a version of the formulation evaluated in Phase I clinical trials to optimize its pharmacokinetic profile under different dietary conditions (fasted vs. fed). The broader FP187 program was developed for the treatment of relapsing-remitting multiple sclerosis (RRMS) and psoriasis, aiming to improve upon the tolerability and efficacy of existing DMF treatments.
- Other names
- dimethyl fumarate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)NF-κBNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on FP187-V2B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP187-V2B.